9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Estimated reading time: < 1 min

Condition: Solid Tumors

Estimated Enrollment: 80

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Frequency and severity of adverse events of INBRX-109,  Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-109,  Area under the serum concentration time curve (AUC) of INBRX-109, Immunogenicity of INBRX-109

Interventions: INBRX-109 – multivalent DR5 agonist antibody,

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Sequential Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: May 2020

Completion Date: July 2020

Last  Posted Date: July 19, 2019

Location: HonorHealth Research Institute, Scottsdale, Arizona, United States

Website Link: https://ClinicalTrials.gov/show/NCT03715933

Was this article helpful?
Dislike 0